Monthly Archives: February 2017

Home/2017/February

New Data Indicates Imatinib Boosts Long-Term Survival for Some GIST Patients

A significant finding from a newly published study in JAMA Oncology, indicates that nearly one-fourth of GIST patients with advanced disease initially treated with imatinib will survive for ten years or more. The study, [...]

By |2018-10-30T09:19:32-04:00February 27th, 2017|News, Research|

The Life Raft Group Patient Registry in Review 2016

The Life Raft Group Patient Registry has over 15 years of self-reported and clinical data encompassing 35 years of patient history crossing institutional boundaries. The Patient Registry has 1703 patients from 67 countries, [...]

By |2018-10-30T09:19:42-04:00February 24th, 2017|News, Newsletter, Patient Registry|

Collaboration Lays the Groundwork for Breakthroughs in GIST

This article originally appeared in the January 30th edition of Cure Today. Less than two decades ago, Gleevec (imatinib) drastically changed the frontline treatment for patients with gastrointestinal stromal tumors (GIST). However, as patients [...]

By |2018-10-30T09:20:36-04:00February 24th, 2017|News, Newsletter, Research|

Cancerversary – Kimberly Glass – 10 years

I celebrate my ten-year “cancerversary” on January 31st.  I can’t believe it’s been 10 years!  I will celebrate by spending some intentional time with my family, including my beautiful 16 month-old daughter, Katelyn.  My [...]

By |2018-10-30T09:22:19-04:00February 24th, 2017|Cancerversary, Member Stories, Newsletter|
Go to Top